MGC Pharmaceuticals Limited
MGCLF · OTC
12/30/2023 | 6/30/2023 | 12/30/2022 | 6/30/2022 | |
|---|---|---|---|---|
| Revenue | $600 | $725 | $2,663 | $2,166 |
| % Growth | -17.3% | -72.8% | 22.9% | – |
| Cost of Goods Sold | $1,182 | $887 | $1,590 | $1,053 |
| Gross Profit | -$582 | -$162 | $1,073 | $1,113 |
| % Margin | -97.1% | -22.3% | 40.3% | 51.4% |
| R&D Expenses | $0 | $2,262 | $0 | $4,242 |
| G&A Expenses | $0 | $6,305 | $7,555 | $5,962 |
| SG&A Expenses | $5,947 | $6,853 | $7,395 | $7,117 |
| Sales & Mktg Exp. | $0 | $927 | -$161 | $1,009 |
| Other Operating Expenses | $0 | $0 | $0 | -$1,713 |
| Operating Expenses | $5,947 | $6,853 | $7,395 | $8,830 |
| Operating Income | -$6,530 | -$7,014 | -$6,322 | -$7,717 |
| % Margin | -1,089.2% | -967.6% | -237.4% | -356.3% |
| Other Income/Exp. Net | -$564 | -$2,927 | -$4,558 | -$5,446 |
| Pre-Tax Income | -$7,094 | -$9,941 | -$10,880 | -$13,163 |
| Tax Expense | -$18 | $0 | $2 | -$254 |
| Net Income | -$7,076 | -$9,941 | -$10,882 | -$12,909 |
| % Margin | -1,180.2% | -1,371.3% | -408.6% | -596% |
| EPS | -0.003 | -3.27 | -3.8 | -4.73 |
| % Growth | 99.9% | 13.9% | 19.7% | – |
| EPS Diluted | -0.003 | -3.27 | -3.8 | -4.73 |
| Weighted Avg Shares Out | 2,309,500 | 3,042 | 2,866 | 2,728 |
| Weighted Avg Shares Out Dil | 2,309,500 | 3,042 | 2,866 | 2,728 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $153 | $104 | $98 |
| Interest Expense | $467 | $153 | $104 | $98 |
| Depreciation & Amortization | $655 | $379 | $161 | $189 |
| EBITDA | -$5,972 | -$9,528 | -$10,806 | -$7,552 |
| % Margin | -996.2% | -1,314.4% | -405.8% | -348.7% |